Full-Time

Director – Central Statistical Monitoring

Posted on 5/9/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$187.1k - $247.1k/yr

+ Annual Bonus + Incentive Compensation + Equity Awards + Employee Stock Purchase Plan

Remote in USA

Remote

Category
Biology & Biotech (1)
Required Skills
Power BI
biostatistics
Requirements
  • Master's degree with 7 years' experience or Ph.D with 5 years' experience in biostatistics/statistics or related quantitative field
  • Demonstrated experience in clinical trial statistics
  • RBQM/CSM, and signal triage
  • Strong stakeholder management and communication skills
  • Experience with model lifecycle management, validation, and documentation for audits/inspections
  • Microsoft Office and Power BI skills
  • Occasional travel is expected
Responsibilities
  • Design and validation of monitoring analytics: Develop and maintain statistical risk indicators (Key Risk Indicators), anomaly detection methods, and monitoring tools appropriate for study purpose and data flows.
  • Partner with study team to specify data derivations, edit checks, and analytic data snapshots required by Central Statistical Monitoring algorithms.
  • Validate models and algorithms: assumptions, diagnostics, false positive/false negative rates, sensitivity analyses, and reproducibility.
  • Signal detection, characterization, and prioritization: Implement processes to detect candidate signals across sites, subjects, and data domains (safety, efficacy, conduct, data quality).
  • Characterize signals by magnitude, specificity, temporal dynamics, covariate dependence, and uncertainty; provide quantitative rationale for prioritization.
  • Define and apply confidence thresholds, tiering logic (e.g., high/medium/low), and criteria for automatic alerts versus human triage.
  • Cross-functional interpretation and communication: Produce tiered deliverables: one-line headline for executives, concise operational briefs for GCO, and detailed technical appendices for analytic teams.
  • Translate statistical uncertainty and model assumptions into concrete, pragmatic next actions for operations and clinical follow-up for medical monitors.
  • Operationalization and decision logic: Co-design decision trees, playbooks mapping signal types to investigative workflows, escalation paths, and CAPA triggers.
  • Ensure feedback loops: incorporate investigation outcomes (true/false/insufficient) to recalibrate models and to improve data collection or derivation rules.
  • Participate in RBQM governance meetings to align statistical approaches with study risk tolerances and regulatory expectations.
  • Training, governance, and stakeholder enablement: Develop and deliver training modules for clinical monitors, safety officers, DM staff, and study teams on interpreting CSM outputs and required actions.
  • Provide statistical support during audits/inspections and contribute to CAPA design when monitoring uncovers systemic issues.
  • Act as a change agent: promote a risk-based mindset, help define governance criteria, and support SOP updates.
  • Performance monitoring and continuous improvement: Define KPIs for CSM effectiveness: time-to-investigation, confirmation rate, and downstream corrective actions.
  • Monitor performance dashboards, conduct periodic reviews, and implement improvements to models, thresholds, and communication templates.
  • Supervisory Responsibilities: Yes

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • BRUKINSA sales reached $3.9B in 2025, growing 49% year-over-year.
  • TEVIMBRA plus ZIIHERA shows extended survival versus trastuzumab in gastric cancer.
  • Three solid tumor programs advancing to late-stage trials with 60+ abstracts.

What critics are saying

  • BRUKINSA represents 73% of revenue; market share loss to competitors accelerates decline.
  • BEQALZI conditional approval requires CELESTIAL-RRMCL Phase 3 trial success by 2027.
  • Generic ibrutinib competition by 2027-2028 forces BRUKINSA price cuts or market share loss.

What makes BeOne unique

  • BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL.
  • BEQALZI is first BCL2 inhibitor approved for relapsed/refractory mantle cell lymphoma.
  • Global GMP manufacturing network enables cost-efficient drug development across 45+ countries.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at BeOne who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

5%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...